Outlook Therapeutics (OTLK) Q3 2024 earnings summary

Executive summary

• Achieved EU and UK marketing authorizations for LYTENAVA (bevacizumab gamma) for wet AMD, securing 10 years of exclusivity in the EU.

• Advancing toward commercial launch in Europe and the UK, with product availability expected in the first half of 2025.

• NORSE EIGHT clinical trial for U.S. approval is underway, with full enrollment expected by Q3 2024, topline results in Q4 2024, and BLA resubmission to FDA planned for Q1 2025.

• No product sales revenue to date; operations funded by equity and debt offerings totaling $531M since inception.

• Substantial doubt exists about ability to continue as a going concern without additional financing, though warrant exercises could extend runway through 2025.

Financial highlights

• Net income of $44.4M for Q3 FY2024, driven by a $59.4M gain from change in fair value of warrant liability; adjusted net loss for Q3 FY2024 was $19.2M.

• Research and development expenses were $11.2M for the quarter, up year-over-year, and $29.2M for the nine months, mainly due to NORSE EIGHT trial and BLA-related costs.

• General and administrative expenses rose to $8.4M for the quarter and $19.6M for the nine months, reflecting Europe prelaunch costs and increased headcount.

• Cash and cash equivalents as of June 30, 2024, were $32.0M, up from $13.6M at September 30, 2023, due to $60.4M in net proceeds from private placements.

• Outstanding convertible note balance reduced to approximately $30.3M as of July 2024.

Outlook and guidance

• NORSE EIGHT enrollment expected to complete before end of Q3 2024; topline results anticipated in Q4 2024.

• BLA resubmission to FDA targeted for Q1 2025, contingent on NORSE EIGHT results.

• Product launch in Germany and UK expected in first half of 2025; potential US FDA approval in H2 2025.

• Existing cash plus potential warrant exercises may fund operations through 2025, but additional financing is required for long-term sustainability.

• Focus remains on U.S. approval and commercial launch, with ongoing assessment of direct or partnered commercialization outside the U.S.